Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:37:22.123Z.
Calculation as of: 2026-10-06T15:37:22.123Z.
Quote observation: 2026-10-06T15:32:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a560454fa7ec99f8e1b664e45bbeeb036d535f564db40397f61edcd9a9056247
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Lexaria Bioscience Corp.
Market Cap
$4.79M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $4.79M | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.69M | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.94M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.16M | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.19M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
